Lava Therapeutics is developing novel bispecific antibody therapeutics for cancer that are at the cutting edge of antibody development. Chris Morrison from Nature Reviews Drug Discovery discusses the state of the art of domain antibody technology.
Nature Reviews Drug Discovery
Dual-targeting concepts enabled by bispecific antibodies hold great therapeutic promise. Our comprehensive review on bispecific antibodies, their mechanisms and the current clinical pipeline has published in the leading review journal Nature Reviews Drug Discovery.
Antibody Engineering and Therapeutics Conference
Paul Parren and Kerry Chester are the scientific organizers of the second European Antibody Engineering and Therapeutics conference. Join them June 12-13 at the Postillion Hotel in Amsterdam. The program will kick of with keynotes by Hans Clevers, Jane …
News from the Keystone Symposium “Antibodies as Drugs”
The Keystone Symposia Antibodies as Drugs: Translating Molecules into Treatments was highly successful with many outstanding scientists presenting lots of new data. We welcomed 246 attendees including 28 speakers, 28 students and 21 postdocs from 22 countries. …
Antibodies as Drugs
Paul Parren and Erica Ollmann Saphire are the scientific organizers of the Keystone Symposia Conference: Antibodies as Drugs. Join them in Whistler, BC, Canada. The program can be found here.
…
Novel insights in immune protection
Our immune system is continuously on the lookout for intruders (e.g. bacteria or viruses) or rogue cells (e.g. infected, damaged or cancerous cells) that represent a potential danger to our health. Sentinel proteins, such as the complement protein C1, play …
Targeting AXL: a promising new strategy for tumor treatment
Novel drug combinations that are designed to address tumor heterogeneity are urgently needed. In an Advance Online Publication in Nature Medicine, a group led by Paul Parren at Genmab and Daniel Peeper at the Netherlands Cancer Institute describe the generation, …